Beraprost
ApprovedSmall molecule
AstellasBeraprost is one of 46 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Approved.
2
Indications
2
Total Trials
0
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
676 competitors in Type 2 Diabetes Mellitus
#DrugCompanyPhaseTrials
1Beraprost
AstellasApproved
Tanzeum
GSKPreclinical
Adenocard
AstellasPreclinical
NOVOLIN R
Novo NordiskPreclinical
Cipro
BayerPreclinical
Myrbetriq
AstellasPreclinical
Golytely
BayerPreclinical
Dostinex
PfizerPreclinical
Lantus
SanofiPreclinical
Lixisenatide
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Beraprost. EMBL-EBI & Wellcome Sanger Institute.
- [4]